Save up -80% on Fibrinogen Concentrate (Human)
Note: this is a drug discount program, not an insurance plan.
2018 Price of Fibrinogen Concentrate (Human)
* price without discount in nearest pharmacy. Price may vary.
We offer free Fibrinogen Concentrate (Human) coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Fibrinogen Concentrate (Human) every time. What are you waiting for? Claim your prescription drug card now!
Fibrinogen Concentrate (Human) volume of distribution
Mean volume of distribution is 52.7 mL/kg.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Fibrinogen Concentrate (Human)
Fibrinogen Concentrate (Human) is a preparation of coagulation factors prepared from pooled human plasma. Also known as “fibrin glue” or “fibrin sealant”, the majority of available formulations (Artiss, Tisseel, Raplixa, TachoSil, Evacil, and Evarrest) contain a mixture of pooled plasma-derived fibrinogen and the enzyme thrombin. Upon reconstitution and mixing, the two components mimic the final stage in the coagulation cascade where thrombin cleaves fibrinogen into fibrin, the main building block required for blood clot formation. Due to this ability to rapidly form a fibrin clot, these two-component mixtures are indicated for the control of bleeding during surgery (Tisseel, Raplixa, TachoSil, Evicel, Evarrest), to prevent leakage from colonic anastomoses following the reversal of temporary colostomies (Tisseel), to adhere autologous skin grafts to surgically prepared wound beds resulting from burns (Artiss), and to adhere tissue flaps during facial rhytidectomy surgery (Artiss). Fibrinogen concentrate is also available as a single component derived from pooled human plasma as the product RiaSTAP. After administration, fibrinogen would be cleaved by endogenous thrombin. RiaSTAP is indicated as a fibrinogen replacement therapy for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Fibrinogen Concentrate (Human) mechanism of action
Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (A , B and ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the A and B chains releasing fibrinopeptides A and B (FPA and FPB, respectively). FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers. The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis. Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.
Dosage forms of Fibrinogen Concentrate (Human)
|Sealant powder||Epilesional use|
|Injection, powder, lyophilized, for solution||intravenous||1300 mg/50mL|
Coagulation Factor I Factor I
Baxter Healthcare Corporation
Indication of Fibrinogen Concentrate (Human)
For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Toxicity of Fibrinogen Concentrate (Human)
RX24 Drugs Disclaimer: before buying a Fibrinogen Concentrate (Human) on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.